These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 38411946)
1. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells. Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946 [TBL] [Abstract][Full Text] [Related]
2. Newcastle Disease Virus V Protein Degrades Mitochondrial Antiviral Signaling Protein To Inhibit Host Type I Interferon Production via E3 Ubiquitin Ligase RNF5. Sun Y; Zheng H; Yu S; Ding Y; Wu W; Mao X; Liao Y; Meng C; Ur Rehman Z; Tan L; Song C; Qiu X; Wu F; Ding C J Virol; 2019 Sep; 93(18):. PubMed ID: 31270229 [TBL] [Abstract][Full Text] [Related]
3. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
4. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2. Yang WH; Lin CC; Wu J; Chao PY; Chen K; Chen PH; Chi JT Mol Cancer Res; 2021 Jun; 19(6):1005-1014. PubMed ID: 33707306 [TBL] [Abstract][Full Text] [Related]
5. Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells. Kan X; Yin Y; Song C; Tan L; Qiu X; Liao Y; Liu W; Meng S; Sun Y; Ding C iScience; 2021 Aug; 24(8):102837. PubMed ID: 34368653 [TBL] [Abstract][Full Text] [Related]
6. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
8. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A Virol J; 2020 May; 17(1):64. PubMed ID: 32370750 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Zamarin D; Palese P Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889 [TBL] [Abstract][Full Text] [Related]
12. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. Elankumaran S; Rockemann D; Samal SK J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332 [TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virus: a promising agent for tumour immunotherapy. Zhao L; Liu H Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810 [TBL] [Abstract][Full Text] [Related]
14. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Fournier P; Bian H; Szeberényi J; Schirrmacher V Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment. Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246 [TBL] [Abstract][Full Text] [Related]
16. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Gong Y; Tang N; Liu P; Sun Y; Lu S; Liu W; Tan L; Song C; Qiu X; Liao Y; Yu S; Liu X; Lin SH; Ding C Autophagy; 2022 Jul; 18(7):1503-1521. PubMed ID: 34720029 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870 [TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53. Abd-Aziz N; Stanbridge EJ; Shafee N J Gen Virol; 2016 Dec; 97(12):3174-3182. PubMed ID: 27902314 [TBL] [Abstract][Full Text] [Related]
19. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related]
20. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]